TNF and cancer: Selective MYXV replication in cancer cells results from compromised innate antiviral defense pathways (e.g., type I interferon [IFN] and tumor necrosis factor [TNF] antiviral responses)22 or constitutively activated signaling pathways (e.g., phosphatidylinositol 3-kinase [PI3K]/AKT).23